China Medical System Wins Singapore Approval for Vitiligo Cream
Subsidiary Rxilient Medical received Singapore approval on Nov. 3, 2026, for ruxolitinib phosphate cream to treat non-segmental vitiligo with facial involvement in adults and adolescents aged 12 and older. No financial terms or sales impact were disclosed.